Skip to main content
NCBI home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1990 Jul;10:40–43.

Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man.

H J Haisma 1, M A Kessel 1, C Silva 1, M van Muijen 1, J C Roos 1, H Bril 1, H J Martens 1, R McCabe 1, E Boven 1
PMCID: PMC2149503  PMID: 2383479

Abstract

Human IgM monoclonal antibody (MAb) 16.88 recognizes an antigen strongly expressed by colon cancer tissue. We used 131I-labelled 16.88 for biodistribution and pharmacokinetic studies in nude mice bearing WiDr or NIH:OVCAR-3 xenografts. Serum half-life was 8 h. Maximum tumour uptake was between 1 and 8 h after administration and amounted to, respectively, 3% and 1% of the injected dose g-1 for WiDr and NIH:OVCAR-3 tumours. Half-lives in these tumours were approximately 24 h. Tumour to normal colon uptake ratios increased from 2.3 at 24 h to 17 at 5 days after injection. Simultaneously, pharmacokinetic studies were performed in patients with advanced colon cancer reactive with 16.88. They were injected with 5 mCi 131I-16.88 by intravenous infusion over 2 h. Serum half-life was 20 h with greater than 90% of the 131I bound to 16.88. Within 40 h 50% of the injected dose was excreted as free 131I in the urine. In one patient an accelerated clearance was found, possibly caused by pre-existing antibodies reacting with 16.88. None of the patients showed an immune response against 16.88 antibody. Immunoscintigraphy showed positive tumour localization in the majority of the patients, best visualized at later days. We conclude that 16.88 has tumour localization properties while its human origin accounts for the lack of immunogenicity.

Full text

PDF
40

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARTH W. F., WOCHNER R. D., WALDMANN T. A., FAHEY J. L. METABOLISM OF HUMAN GAMMA MACROGLOBULINS. J Clin Invest. 1964 Jun;43:1036–1048. doi: 10.1172/JCI104987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ballou B., Reiland J., Levine G., Knowles B., Hakala T. R. Tumor location using F(ab')2 mu from a monoclonal IgM antibody: pharmacokinetics. J Nucl Med. 1985 Mar;26(3):283–292. [PubMed] [Google Scholar]
  3. Carrasquillo J. A., Krohn K. A., Beaumier P., McGuffin R. W., Brown J. P., Hellström K. E., Hellström I., Larson S. M. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep. 1984 Jan;68(1):317–328. [PubMed] [Google Scholar]
  4. Dairkee S. H., Hackett A. J. Internal antigens accessible in breast cancer: implications for tumor targeting. J Natl Cancer Inst. 1988 Oct 5;80(15):1216–1220. doi: 10.1093/jnci/80.15.1216. [DOI] [PubMed] [Google Scholar]
  5. Goldenberg D. M., Kim E. E., DeLand F. H., Bennett S., Primus F. J. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res. 1980 Aug;40(8 Pt 2):2984–2992. [PubMed] [Google Scholar]
  6. Haisma H. J., Hilgers J., Zurawski V. R., Jr Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method. J Nucl Med. 1986 Dec;27(12):1890–1895. [PubMed] [Google Scholar]
  7. Halpern S. E., Hagan P. L., Chen A., Birdwell C. R., Bartholomew R. M., Burnett K. G., David G. S., Poggenburg K., Merchant B., Carlo D. J. Distribution of radiolabeled human and mouse monoclonal IgM antibodies in murine models. J Nucl Med. 1988 Oct;29(10):1688–1696. [PubMed] [Google Scholar]
  8. Hamilton T. C., Young R. C., Louie K. G., Behrens B. C., McKoy W. M., Grotzinger K. R., Ozols R. F. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 1984 Nov;44(11):5286–5290. [PubMed] [Google Scholar]
  9. Herlyn D., Lubeck M., Sears H., Koprowski H. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods. 1985 Dec 17;85(1):27–38. doi: 10.1016/0022-1759(85)90271-6. [DOI] [PubMed] [Google Scholar]
  10. Jain R. K., Baxter L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988 Dec 15;48(24 Pt 1):7022–7032. [PubMed] [Google Scholar]
  11. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P. A., Jr Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984 Aug 3;72(1):77–89. doi: 10.1016/0022-1759(84)90435-6. [DOI] [PubMed] [Google Scholar]
  12. Mach J. P., Chatal J. F., Lumbroso J. D., Buchegger F., Forni M., Ritschard J., Berche C., Douillard J. Y., Carrel S., Herlyn M. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res. 1983 Nov;43(11):5593–5600. [PubMed] [Google Scholar]
  13. McCabe R. P., Peters L. C., Haspel M. V., Pomato N., Carrasquillo J. A., Hanna M. G., Jr Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors. Cancer Res. 1988 Aug 1;48(15):4348–4353. [PubMed] [Google Scholar]
  14. Moseley K. R., Knapp R. C., Haisma H. J. An assay for the detection of human anti-murine immunoglobulins in the presence of CA125 antigen. J Immunol Methods. 1988 Jan 21;106(1):1–6. doi: 10.1016/0022-1759(88)90264-5. [DOI] [PubMed] [Google Scholar]
  15. Noguchi P., Wallace R., Johnson J., Earley E. M., O'Brien S., Ferrone S., Pellegrino M. A., Milstien J., Needy C., Browne W. Characterization of the WIDR: a human colon carcinoma cell line. In Vitro. 1979 Jun;15(6):401–408. doi: 10.1007/BF02618407. [DOI] [PubMed] [Google Scholar]
  16. Pimm M. V., Armitage N. C., Ballantyne K., Baldwin R. W., Perkins A. C., Durrant L. G., Garnett M. C., Hardcastle J. D. Imaging of primary and metastatic colorectal carcinoma with monoclonal antibody 791T/36 and the therapeutic potential of antibody-drug conjugates. Cancer Detect Prev Suppl. 1987;1:249–262. [PubMed] [Google Scholar]
  17. Shawler D. L., Bartholomew R. M., Smith L. M., Dillman R. O. Human immune response to multiple injections of murine monoclonal IgG. J Immunol. 1985 Aug;135(2):1530–1535. [PubMed] [Google Scholar]
  18. Spitler L. E., del Rio M., Khentigan A., Wedel N. I., Brophy N. A., Miller L. L., Harkonen W. S., Rosendorf L. L., Lee H. M., Mischak R. P. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res. 1987 Mar 15;47(6):1717–1723. [PubMed] [Google Scholar]
  19. Welt S., Mattes M. J., Grando R., Thomson T. M., Leonard R. W., Zanzonico P. B., Bigler R. E., Yeh S., Oettgen H. F., Old L. J. Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice. Proc Natl Acad Sci U S A. 1987 Jun;84(12):4200–4204. doi: 10.1073/pnas.84.12.4200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Zuckier L. S., Rodriguez L. D., Scharff M. D. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med. 1989 Jul;19(3):166–186. doi: 10.1016/s0001-2998(89)80012-1. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES